Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Biogen Idec (NQ:BIIB)

181.48 +0.73 (+0.40%)
Streaming Delayed Price Updated: 11:40 AM EST, Dec 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biogen Idec

< Previous 1 2 3 4 5 6 7 8 9
...
56 57 Next >
News headline image
Stoke Therapeutics and Biogen Announce Presentations at the 2025 American Epilepsy Society Annual Meeting
From Stoke Therapeutics, Inc.
Via Business Wire
News headline image
Novo Nordisk Shares Plunge as Alzheimer's Drug Trial Fails to Meet Primary Endpoint
Copenhagen, Denmark – November 24, 2025 – Novo Nordisk's (CPH: NOVO B) stock experienced a significant and immediate downturn today, plummeting by over 10% in early trading, following the announcement... 
Via MarketMinute
News headline image
Which S&P500 stocks are moving before the opening bell on Monday? ↗
Before the opening bell on Monday, let's take a glimpse of the US markets and explore the S&P500 top gainers and losers in today's pre-market session. 
Via Chartmill
News headline image
Earnings Scheduled For October 30, 2025 ↗
 
Via Benzinga
Biogen Licenses Vanqua Bio’s Immunology Drug In $1.06B Deal ↗
Via Stocktwits
News headline image
Biogen and Dayra Therapeutics Announce Research Collaboration to Discover and Develop Oral Macrocyclic Peptides for a Range of Immunological Conditions
From Biogen Inc.
Via GlobeNewswire
News headline image
AbbVie, Biogen, BioMarin Pharmaceutical, DexCom, and Abbott Laboratories Stocks Trade Up, What You Need To Know
A number of stocks jumped in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an interest rate cut. New York Federal Reserve President John Williams stated... 
Via StockStory
Topics Economy Government World Trade
News headline image
Biogen to Highlight New Lecanemab Data and Scientific Advances at the 18th Clinical Trials on Alzheimer’s Disease Conference
From Biogen Inc.
Via GlobeNewswire
News headline image
Uncover the latest developments among S&P500 stocks in today's session. ↗
Curious about the top performers within the S&P500 index in the middle of the day on Tuesday? Dive into the list of today's session's top gainers and losers for a comprehensive overview. 
Via Chartmill
News headline image
Biogen and Stoke Therapeutics Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral Impairments
From Biogen Inc.
Via GlobeNewswire
News headline image
High Dose Regimen of Nusinersen Receives Positive CHMP Opinion for the Treatment of Spinal Muscular Atrophy
From Biogen Inc.
Via GlobeNewswire
News headline image
Biogen Completes Acquisition of Alcyone Therapeutics
From Biogen Inc.
Via GlobeNewswire
News headline image
Explore the top gainers and losers within the S&P500 index in today's session. ↗
Stay updated with the movement of S&P500 stocks in today's session. Discover which S&P500 stocks are making waves on Thursday. 
Via Chartmill
News headline image
5 Insightful Analyst Questions From Biogen’s Q3 Earnings Call
Biogen’s third quarter results came in ahead of Wall Street’s revenue and profit expectations, driven by robust performance from recently launched products and continued strength in its multiple... 
Via StockStory
Topics Earnings
News headline image
Biogen to Highlight Scientific Progress in Rare Kidney Disease at American Society of Nephrology (ASN) Kidney Week 2025
From Biogen Inc.
Via GlobeNewswire
News headline image
BIIB Q3 Deep Dive: New Product Launches Offset Guidance Cut, R&D Pipeline Expands
Biotech company Biogen (NASDAQ:BIIB) announced better-than-expected revenue in Q3 CY2025, with sales up 2.8% year on year to $2.53 billion. Its non-GAAP profit of $4.81 per share was 23.9% above... 
Via StockStory
News headline image
Biogen (NASDAQ:BIIB) Beats Q3 Sales Expectations
Biotech company Biogen (NASDAQ:BIIB) reported Q3 CY2025 results topping the market’s revenue expectations, with sales up 2.8% year on year to $2.53 billion. Its non-GAAP profit of $4.81 per share was... 
Via StockStory
Topics Artificial Intelligence
News headline image
Biogen Sinks Back Into A Buy Zone After Cutting Its Profit Guide ↗
Biogen stock fell early Thursday after the biotech company cut its 2025 profit outlook due to an expected tax charge. 
Via Investor's Business Daily
News headline image
Examining the Future: Biogen's Earnings Outlook ↗
 
Via Benzinga
News headline image
Biogen (BIIB) Reports Earnings Tomorrow: What To Expect
Biotech company Biogen (NASDAQ:BIIB) will be announcing earnings results this Thursday before market open. Here’s what to look for. 
Via StockStory
Topics Artificial Intelligence
News headline image
Biogen's Immunology Pipeline Has Long-Term Potential: Analyst ↗
Biogen gains exclusive rights to Vanqua's oral C5aR1 antagonist, boosting its immunology pipeline with potential across multiple immune diseases. 
Via Benzinga
News headline image
Biogen Licenses Oral C5aR1 Antagonist from Vanqua Bio to Expand Immunology Portfolio
From Biogen Inc.
Via GlobeNewswire
News headline image
3 Profitable Stocks We Steer Clear Of
While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my... 
Via StockStory
News headline image
Biogen to Present Additional Results from Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus at ACR Convergence 2025
From Biogen Inc.
Via GlobeNewswire
News headline image
ARPA-H Taps Former DARPA Innovator to Ignite High-Risk, High-Reward Health Tech Revolution
In a move poised to reshape the landscape of biomedical innovation, the United States government officially appointed Dr. Renee Wegrzyn, a distinguished former official from the Defense Advanced... 
Via TokenRing AI
Topics Artificial Intelligence Intellectual Property
News headline image
J.L. Bainbridge Exits Most of Biogen Stake as Biotech Stock Eyes Turnaround ↗
Via The Motley Fool
News headline image
Small-Cap Biotech Climb Bio's Lead Drug Candidate Has Larger Long-Term Opportunity ↗
William Blair assigns Climb Bio an Outperform rating, projecting peak sales of $1.9 billion and long-term growth for its therapy pipeline. 
Via Benzinga
News headline image
3 Reasons BIIB is Risky and 1 Stock to Buy Instead
Biogen has followed the market’s trajectory closely, rising in tandem with the S&P 500 over the past six months. The stock has climbed by 26.6% to $146 per share while the index has gained 26.5%. 
Via StockStory
Topics Government Stocks World Trade
News headline image
1 Healthcare Stock to Research Further and 2 We Find Risky
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. But speed bumps such as inventory destockings have persisted in the wake of COVID-19,... 
Via StockStory
Topics Stocks
News headline image
LEQEMBI® IQLIK™(lecanemab-irmb) Subcutaneous Autoinjector Named to TIME’s “Best Inventions of 2025”
From Biogen Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
56 57 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.